ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
The concept of immunotherapy or boosting the body’s immune system to target tumors was first practically applied in the early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results